A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 clinical trials showed up to 24% body weight reduction over 48 weeks. Still investigational and not FDA approved as of 2026.
Dosing & Protocols
Start at 0.5-1mg/week subcutaneous, titrate slowly. Clinical doses ranged 1mg-12mg/week. Conservative titration strongly recommended due to potency.
Side Effects
Nausea very common during titration, vomiting, diarrhea, decreased appetite. Contraindicated with personal or family history of medullary thyroid carcinoma or MEN2. Pancreatitis risk (class effect).
Interactions & Contraindications
Do not combine with other GLP-1 agonists (semaglutide, tirzepatide). Monitor closely with insulin or sulfonylureas.
Storage
Lyophilized: freeze. Reconstituted: refrigerate, use within 28 days.
Disclaimer: All information is for research purposes only. Not medical advice.